Skip to Content
Merck

Exosomes: novel effectors of human platelet lysate activity.

European cells & materials (2014-09-23)
E Torreggiani, F Perut, L Roncuzzi, N Zini, S R Baglìo, N Baldini
ABSTRACT

Despite the popularity of platelet-rich plasma (PRP) and platelet lysate (PL) in orthopaedic practice, the mechanism of action and the effectiveness of these therapeutic tools are still controversial. So far, the activity of PRP and PL has been associated with different growth factors (GF) released during platelet degranulation. This study, for the first time, identifies exosomes, nanosized vesicles released in the extracellular compartment by a number of elements, including platelets, as one of the effectors of PL activity. Exosomes were isolated from human PL by differential ultracentrifugation, and analysed by electron microscopy and Western blotting. Bone marrow stromal cells (MSC) treated with three different exosome concentrations (0.6 μg, 5 μg and 50 μg) showed a significant, dose-dependent increase in cell proliferation and migration compared to the control. In addition, osteogenic differentiation assays demonstrated that exosome concentration differently affected the ability of MSC to deposit mineralised matrix. Finally, the analysis of exosome protein content revealed a higher amount of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB) and transforming growth factor beta 1 (TGF-β1) as compared to PL. In regards to RNA content, an enrichment of small RNAs in exosomes as compared to donor platelets has been found. These results suggest that exosomes consistently contribute to PL activity and could represent an advantageous nanodelivery system for cell-free regeneration therapies.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sulfuric acid concentrate, 0.1 M H2SO4 in water (0.2N), eluent concentrate for IC
Sigma-Aldrich
Sodium fluoride, 99.99% trace metals basis
Supelco
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Sodium fluoride, anhydrous, powder, 99.99% trace metals basis
Supelco
Fluoride ion solution for ISE, 0.1 M F-, for ion-selective electrodes
Sigma-Aldrich
Sodium fluoride, BioXtra, ≥99%
Sigma-Aldrich
Sodium fluoride, BioReagent, suitable for insect cell culture, ≥99%
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, ≥90% (HPLC)
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
Sodium fluoride 0.5 M solution
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Supelco
Sodium Fluoride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium fluoride, ReagentPlus®, ≥99%
Sigma-Aldrich
Sodium fluoride, puriss., meets analytical specification of Ph. Eur., BP, USP, 98.5-100.5% (calc. to the dried substance)
Sigma-Aldrich
Sodium fluoride, ACS reagent, ≥99%
Sigma-Aldrich
Sodium chloride, 99.999% trace metals basis
Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Sigma-Aldrich
Sodium chloride solution, 0.85%